Teva has moved fast to match Dr Reddy’s Laboratories’ complete six-strength offering of generic Revlimid (lenalidomide) products in the US.

All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.

Biogen has launched the Samsung Bioepis-developed Byooviz version of Lucentis in Canada, marking the first and only ranibizumab biosimilar to be approved and introduced in the market.

Indian firm Natco is continuing to build its US pipeline and ex-India geographic presence, the company’s management told investors, in the wake of announcing a major paragraph IV patent challenge opportunity.